Wedbush reaffirmed their outperform rating on shares of Aimmune Therapeutics (NASDAQ:AIMT) in a research report report published on Friday morning. They currently have a $70.00 price objective on the biotechnology company’s stock.
AIMT has been the topic of a number of other reports. Piper Jaffray Companies set a $38.00 target price on shares of Aimmune Therapeutics and gave the stock a buy rating in a report on Saturday, October 21st. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a sell rating to a hold rating in a report on Tuesday, August 29th. Roth Capital started coverage on shares of Aimmune Therapeutics in a report on Monday, November 20th. They issued a buy rating and a $60.00 target price on the stock. BidaskClub lowered shares of Aimmune Therapeutics from a hold rating to a sell rating in a report on Friday, August 11th. Finally, Credit Suisse Group boosted their price target on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the company an outperform rating in a report on Monday, October 23rd. Two equities research analysts have rated the stock with a sell rating and five have given a buy rating to the stock. Aimmune Therapeutics presently has an average rating of Hold and an average target price of $49.40.
Shares of Aimmune Therapeutics (NASDAQ AIMT) opened at $36.20 on Friday. Aimmune Therapeutics has a fifty-two week low of $15.97 and a fifty-two week high of $38.86.
Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.09. sell-side analysts predict that Aimmune Therapeutics will post -2.57 earnings per share for the current fiscal year.
In other news, insider Susan E. Barrowcliffe sold 18,390 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $22.00, for a total transaction of $404,580.00. Following the sale, the insider now owns 3,223 shares in the company, valued at $70,906. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Susan E. Barrowcliffe sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $25.00, for a total transaction of $500,000.00. Following the sale, the insider now owns 20,000 shares in the company, valued at approximately $500,000. The disclosure for this sale can be found here. Insiders have sold 321,470 shares of company stock worth $8,538,994 in the last 90 days. 17.59% of the stock is owned by company insiders.
Several hedge funds have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. raised its holdings in shares of Aimmune Therapeutics by 10.2% during the third quarter. Point72 Asset Management L.P. now owns 1,098,087 shares of the biotechnology company’s stock valued at $27,222,000 after acquiring an additional 101,855 shares during the period. Schwab Charles Investment Management Inc. grew its position in Aimmune Therapeutics by 4.6% during the third quarter. Schwab Charles Investment Management Inc. now owns 110,580 shares of the biotechnology company’s stock valued at $2,742,000 after purchasing an additional 4,891 shares in the last quarter. Wells Fargo & Company MN grew its position in Aimmune Therapeutics by 3.4% during the third quarter. Wells Fargo & Company MN now owns 61,266 shares of the biotechnology company’s stock valued at $1,519,000 after purchasing an additional 2,025 shares in the last quarter. Citadel Advisors LLC grew its position in Aimmune Therapeutics by 3,092.5% during the third quarter. Citadel Advisors LLC now owns 559,641 shares of the biotechnology company’s stock valued at $13,873,000 after purchasing an additional 542,111 shares in the last quarter. Finally, Schroder Investment Management Group purchased a new position in Aimmune Therapeutics during the third quarter valued at approximately $961,000. Institutional investors and hedge funds own 73.34% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Aimmune Therapeutics (AIMT) Receives “Outperform” Rating from Wedbush” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/05/aimmune-therapeutics-aimt-receives-outperform-rating-from-wedbush.html.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.